Format

Send to

Choose Destination
Clin Med (Lond). 2016 Feb;16(1):62-5. doi: 10.7861/clinmedicine.16-1-62.

Non-melanoma skin cancer.

Author information

1
Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, UK.
2
St John's Institute of Dermatology, St Thomas' Hospital, London, UK.
3
Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, UK john.lear@cmft.nhs.uk.

Abstract

Non-melanoma skin cancer (NMSC) comprises basal cell carcinoma (BCC) and squamous cell carcinoma, together with a host of rare tumours. NMSC is the commonest malignancy among Caucasians and its incidence continues to rise annually. Exposure to UV radiation initiates approximately 90% of NMSC, causing malignant transformation of keratinocytes and suppression of the inflammatory response. Risk factors include sun exposure and immunosuppression. There are several subtypes of BCC, although histological overlap is common. Surgery has traditionally been regarded as the 'gold-standard' treatment, offering excellent cure rates and cosmetic results. Other treatment modalities include physical destruction (radiotherapy, curettage and cautery, and cryotherapy), chemical destruction (photodynamic therapy and topical 5-flurouracil) and immunomodulatory therapy (topical imiquimod). The recent development of novel hedgehog pathway inhibitors for high-risk BCC (including oral vismodegib and sonidegib) may represent a paradigm shift towards medical management of NMSC.

KEYWORDS:

Non-melanoma skin cancer; basal cell carcinoma; dermatology; squamous cell carcinoma; surgery

PMID:
26833519
DOI:
10.7861/clinmedicine.16-1-62
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center